Anzeige
Mehr »
Donnerstag, 14.08.2025 - Börsentäglich über 12.000 News
Setup für DOGE & LTC Mining läuft an - und diese Aktie steht in der ersten Reihe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40B6X | ISIN: US9495031067 | Ticker-Symbol:
NASDAQ
13.08.25 | 20:20
0,696 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
WELLGISTICS HEALTH INC Chart 1 Jahr
5-Tage-Chart
WELLGISTICS HEALTH INC 5-Tage-Chart
ACCESS Newswire
141 Leser
Artikel bewerten:
(0)

Wellgistics Health, Inc.: Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement ("ELOC") with Hudson Global Ventures, LLC.

The ELOC was an effective tool that nearly doubled the Company's original IPO raise. The decision to terminate the agreement reflects a strategic shift toward accretive financing and reinforces its aim of long-term shareholder value creation.

Management cited strong execution in expanding its independent pharmacy network, accelerating adoption of its AI-powered prescription routing technology and payment platforms, and creating a strong pipeline for growth opportunities with manufacturer direct-to-patient (DTP) platforms as drivers behind the move. This unique approach is designed to bypass traditional PBM barriers, increase manufacturer margins, and accelerate patient access.

"From a financial standpoint, terminating the ELOC aligns with our disciplined approach to capital structure and shareholder equity preservation," said Mark DiSiena, Chief Financial Officer of Wellgistics Health. "It allows us to secure more favorable funding opportunities so we can focus on our strategic plans, optimize our cost of capital, and pursue options that better reflect our growth trajectory."

"This decision reflects the discipline we're bringing to every part of the business," said Brian Norton, Chief Executive Officer of Wellgistics Health. "We've moved past the challenges of our opening quarters and are entering a new chapter built on operational strength and strategic execution. We're ready to show the market what we're truly capable of - delivering smarter, faster access to medicine, empowering independent pharmacies, and creating lasting value across the healthcare ecosystem."

About Wellgistics Health

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health offers compliant, end-to-end solutions that restore access, transparency, and trust in U.S. healthcare.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Media Contact: media@wellgisticshealth.com

Investor Relations: investors@wellgisticshealth.com

Investor Relations Contact:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-terminates-equity-line-of-credit-to-further-suppor-1060985

© 2025 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.